Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.

International journal of cancer - 1 Dec 2010

Srivastava Minu K, Bosch Jacobus J, Wilson Ashley L, Edelman Martin J, Ostrand-Rosenberg Suzanne

Abstract excerpt

Nonsmall cell lung cancer (NSCLC) is the major cause of lung cancer-related deaths in the United States. We are developing cell-based vaccines as a new approach for the treatment of NSCLC. NSCLC is broadly divided into 3 histologic subtypes: adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Since these subtypes are derived from the same progenitor cells, we hypothesized that they share common...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Bronchiolo-Alveolar
Share to B7-1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Vaccines

Share to CD4-Positive T-Lymphocytes

Share to Cross Reactions

Share to HLA-DR Antigens

Share to Lymphocyte Activation

Share to Myeloid Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 20473949
DOI: 10.1002/ijc.25462
PMCID: PMC2947152

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells.PMID 20473949Read ↗

Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profileSemantic proximity Read ↗

MHC class II expression in lung cancer.Semantic proximity Read ↗

Identification of a New Cancer/Germline Gene,<i>KK-LC-1</i>, Encoding an Antigen Recognized by Autologous CTL Induced on Human Lung AdenocarcinomaSemantic proximity Read ↗

Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer.Semantic proximity Read ↗

HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.Semantic proximity Read ↗

Prospects for Combined Treatment of Non-Small Cell Lung Cancer Using Autologous Activated LymphocytesSemantic proximity Read ↗

An innovative treatment for lung cancer using gene-engineered human-induced pluripotent stem cell- derived natural killer cellsSemantic proximity Read ↗

Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic ActivitySemantic proximity Read ↗

Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.